1. Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med Off Publ Soc Nucl Med. 2013;54(6):855–60.
2. Breeman WAP, Chan HS, de Zanger RMS, Konijnenberg MK, Blois E de. Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT. Curr Radiopharm. 2015
3. Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiogr Rev Publ Radiol Soc North Am Inc. 2015;35(2):500–16.
4. Notni J, Pohle K, Wester H-J. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res. 2012;2(1):28.
5. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3(1):81–5.